QURE
uniQure N.V.
September 23, 2026 · after-hours
- Rarity
- 1.96
- Peak move
- −13.81%
- Float cap
- $2.4B
uniQure N.V. is a gene therapy company developing single treatments with potentially curative results for patients with rare and other devastating diseases. It is advancing clinical candidates for Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis caused by SOD1 mutations. These investigational therapies are intended for patients with serious, rare conditions and are not yet approved for commercial sale.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingWeiss Ratings upgraded its outlook on uniQure (NASDAQ: QURE) on September 21, 2026, setting a "Sell (D-)" rating on the shares.